Primary Study On The Re-Endothelialization Of Homologous Vavle Via Recipient's Endothelial Cells Differentiated From Bone Mesenchymal Cells In Vitro

Homologous valve(HV) is an important repair material and used extensively in the cardiovascular surgical operation. As a kind of variant tissue transplantation, immunological rejection is unavoidable after transplantation, and this rejection will cause HV's calcification and failure, so the long-term clinical effect is not satisfactory. Edothelial cells(ECs) on HV possesses multiple action, such as cellular barrier, endocrine, anti- thromb. In abstracto, ECs can prolong the HV' s service life. How ever, ECs' immunogenicity is the strongest on HV and it is easy to cause HV' s immune decline. If there is no ECs' barrer, HV' s fiber will exposed to recipient' s blood straightly, and the calcification and failure will also occure on HV. So, the question how to possess the integrity of HV' s structure and function, degrade immune decline, and prolong HV' s service life, puzzled all the cardiovascular surgeons.In abstracto, applying recipient's ECs to take the place of the initial ECs can solve the puzzle. Unfortuenately, after so many years reseach, a convenient, available and effective method still not emerge. Up to the present, there are two kind of mode on the re-endothelialization of HV: in vivo and in vitro. Re-endothelialization in vivo is, transplanting the primed HV into the recipient, recipient' s ECs growth, creep and then covering the surface of HV. Re-endothelialization in vitro is, culturing recipient' s ECs in vitro and then implanting them onto the surface of HV. During...